Standout Papers
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial (2019)
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the
BRIDGE Study (2015) - Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020)
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021)
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (2015)
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version (2011)
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial (2015)
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial (2013)
- Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) (2003)
- CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019)
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial (2014)
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (2014)
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib (2014)
- Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma (2019)
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma (2020)
- Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations (2018)
- Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection (2018)
- Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion (2016)
- The role of hepatic resection in the treatment of hepatocellular cancer (2015)
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
- Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference (2020)
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). (2021)
- LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) (2022)
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis (2021)
- Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024)
- Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023)
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. (2024)
- Breakthroughs in Hepatocellular Carcinoma Therapies (2023)
- Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
Immediate Impact
3 by Nobel laureates 3 from Science/Nature 59 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Works of Masatoshi Kudo being referenced
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
2024 Standout
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Masatoshi Kudo | 30070 | 17249 | 12714 | 1.4k | 47.1k | |
| Peter R. Galle | 18671 | 15648 | 13107 | 1.2k | 53.9k | |
| Masao Omata | 19210 | 17387 | 8803 | 1.0k | 49.9k | |
| Kazuaki Chayama | 14718 | 15457 | 7216 | 1.4k | 44.3k | |
| Andrew X. Zhu | 16657 | 8134 | 12437 | 415 | 33.7k | |
| Vincenzo Mazzaferro | 24135 | 14779 | 7444 | 357 | 36.6k | |
| Masatoshi Makuuchi | 27673 | 13001 | 11537 | 776 | 47.1k | |
| Jordi Bruix | 54115 | 32607 | 11084 | 372 | 72.1k | |
| Gregory J. Gores | 18678 | 19761 | 13911 | 583 | 61.8k | |
| Peter Schirmacher | 10370 | 8936 | 11352 | 673 | 35.7k | |
| Irene Oi‐Lin Ng | 18202 | 10146 | 10970 | 620 | 46.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...